Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17576245 | 0.83 | AKR1C3 (0.44) | SMN1; SMN2GAAMAPTALDH1A1KMT2A | |
| SCHEMBL16730298 | 0.82 | MAPT (0.51) | SMN1; SMN2MAPTALDH1A1KDM4EHTT | |
| SCHEMBL15731795 | 0.81 | PIK3R1 (0.39) | LGMNSMN1; SMN2GAAMAPTALDH1A1 | |
| SCHEMBL16730291 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL6330031 | 0.80 | KMT2A (0.49) | SMN1; SMN2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL16730288 | 0.78 | ALDH1A1 (0.53) | SMN1; SMN2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15628318 | 0.78 | F10 (0.47) | — | |
| SCHEMBL78755 | 0.78 | LGMN (0.67) | LGMNSMN1; SMN2GAARAD52MAPT | |
| SCHEMBL16730424 | 0.78 | ALDH1A1 (0.49) | SMN1; SMN2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL20050092 | 0.78 | ALDH1A1 (0.42) | LGMNSMN1; SMN2GAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| EP-3072892-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
| WO-2015070809-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | 成都苑东药业有限公司 | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | PEPD, F2, XDH | LGMN 2308/4885SMN1; SMN2 4528/4885GAA 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.